IP Library Granted Patent US 10,258,586
Granted Patent B2
US 10,258,586 · App. 15/530,630 · Granted Apr 16, 2019

Methods and compositions for the treatment of diverticulosis

Inventor: Yutaka Niihara (Rolling Hills Estates, CA)
Assignee: Emmanus Medical, Inc.
A61K31/198A23L33/10A23L33/105A23L33/175A23L33/24A23L33/30A61K31/717A61K31/721A61K36/68A23V2002/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,258,586
App. No.
15/530,630
Granted
Apr 16, 2019
Kind
B2
Abstract

The present invention is directed to methods and compositions for the treatment of diverticulosis. It is more specifically directed to compositions including L-glutamine, its salts, or its derivatives, and uses of such compositions in the treatment of diverticulosis. In a method aspect, the present invention provides a method of treating diverticulosis. The method includes ingestion of 0.05 g/kg body weight to 10.0 g/kg body weight of L-glutamine, an L-glutamine salt or an L-glutamine derivative per day by a person who has diverticulosis.

Claims (5)

1. A method of treating diverticulosis, wherein the method consists of ingestion of 0.05 g/kg body weight to 10.0 g/kg body weight of L-glutamine or an L-glutamine salt per day by a person who has diverticulosis, wherein L-glutamine or an L-glutamine salt is the only active ingredient in a suspension or solution, and wherein the person who has diverticulosis has a number of diverticula, and wherein the number of diverticula in the person with diverticulosis is reduced by at least twenty-five percent.

2. The method according to claim 1 , wherein the compound ingested is L-glutamine.

3. The method according to claim 2 , wherein the L-glutamine is ingested as part of an aqueous solution or suspension.

4. The method according to claim 2 , wherein the L-glutamine is ingested for a period of at least three months.

5. The method according to claim 2 , wherein the number of diverticula in the person with diverticulosis is reduced by at least fifty percent.

Assignments (2)
RELEASE OF SECURITY INTEREST Recorded May 4, 2018
From: GPB DEBT HOLDINGS II, LLC
To: EMMAUS LIFE SCIENCES, INC.; EMMAUS MEDICAL, INC.
Reel/Frame 045720/0155 →
SECURITY INTEREST Recorded Jan 3, 2018
From: EMMAUS LIFE SCIENCES, INC.; EMMAUS MEDICAL, INC.
To: GPB DEBT HOLDINGS II, LLC.
Reel/Frame 044527/0094 →
Continuity (3)
Continuation 13694592 · Dec 14, 2012
Provisional Application 61630831 · Dec 19, 2011
Related Publication 20170157080A1 · Jun 8, 2017